A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
ENROLLING
Trial ID:
NCT04065399 Protocol # :
19-467
Phase
I/II
Disease Sites
Lymphoid Leukemia
Myeloid and Monocytic Leukemia
Leukemia, other
Principal Investigator
Stone, Richard, M
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #19-467
19-467